Deep Dive · Consumer — visual story

1 in 8 adults.
A new plate.

Roughly one in eight US adults now takes a GLP-1 medication — one hard number, from a national KFF poll (November 2025). This is that number at real-life size: one generic injector pen per person.

← Read the articleNine scenes — the street, the walk, the stack, the plate, the brief, the shelf, the fog, the bet

Clay previz: eight identical houses on a dawn cul-de-sac, low fog, one streetlamp — Eight houses at dawn. One streetlamp, low fog.

Clay previz: abstract figures walking a town sidewalk, the nearest carrying a violet-clipped tote — Eight walkers on the block — the eighth carries the violet tote.

Clay previz: a generic injector pen resting on a clinic desk, clinician massing behind — The handoff: a generic injector pen slides across the desk.

Deep Dive · Consumer

1 in 8 adults. A new plate.

The one number

Roughly one in eight US adults now takes a GLP-1 medication

KFF poll, November 2025

Not a food

The fastest-moving consumer force in food isn't a food — it's a drug class.

What it moves

GLP-1 adoption is reshaping product design toward high protein, functional fiber, satiety, and muscle retention, accelerating the food-as-medicine shift.

The customer

It also reframes who the customer is.

Not a diet product

A GLP-1 user isn't shopping for a diet product in the old sense — they aren't fighting hunger, they're managing a suppressed appetite and trying not to lose muscle or skip nutrients along the way.

Every bite

A shopper on a GLP-1 eats less, gets full faster, and — if they and their clinician are doing it right — needs every bite to carry more protein and micronutrients.

Clay previz: twenty stacked injector pens reaching a basketball rim, a human figure for scale — 20 pens — 3.0 m, a basketball rim. True scale.

Clay previz: the pen column rising past the curve of the Earth to the ISS at 405 km — 2.7M pens — 405 km, the ISS. The full stack goes 12× higher.

Clay previz: the stack laid across a US map, running from Los Angeles past New York into the Atlantic — Laid down: 4,716 km — LA→NY, then 772 km past.

The one number

That one number — ~1 in 8 — is the whole story, and it's worth being precise about what it is and isn't.

What it is

It's a hard, primary-sourced adoption figure from a national KFF poll. It is not a market-size dollar estimate: there is no credible single-firm number for the “GLP-1 food” category yet, and anyone quoting one is guessing.

The cadence

If each took one weekly dose: ~52 injections every second, around the clock.

Laid down

Multiply that across a one-in-eight slice of adult America and the demand signal is real, even if the addressable market can't yet be sized.

31M pens laid end-to-end reach from Los Angeles to New York — and keep going ~770 km past, out over the Atlantic.

Clay previz placeholder for the inside-the-body scene — S3: the conveyor slows, the hunger lamp dims, the food noise settles.

Scene 3 — Why it changes the plate

Behavioral design targets, not a validated dietary standard — clinical guidance still comes from a physician.

Protein: Preserves lean muscle during rapid weight loss
Functional fiber: Supports digestion and satiety on lower intake
Satiety: Extends fullness so smaller portions feel complete
Muscle retention: Counters lean-mass loss the drugs can accelerate
Micronutrients: Prevents shortfall when total bites drop

Skip to the numbers ↓

The mechanism

GLP-1 receptor agonists work by slowing gastric emptying and blunting appetite, so users simply eat less.

The risk

When total intake falls, the risk isn't calories — it's nutritional shortfall: too little protein to preserve muscle during rapid weight loss, too little fiber for digestion, too few micronutrients per bite.

Denser, not just smaller

The plate doesn't just get smaller; it has to get denser.

The inversion

That inverts decades of “low-calorie, high-volume” positioning.

The winning message

The winning message is no longer “eat more of this for less” but “make the little you eat count.”

The brief

Products aren't chasing indulgence or novelty — they're chasing nutrient density per bite and functional support for a body eating less.

None of these are exotic

None of these are exotic. That's the point: the GLP-1 wave rewards executional discipline on protein and fiber over invention.

Clay previz placeholder for the format line and aisle scenes — S6–S9: the format line, the aisle, the fog, and the plate at first light.

Smaller, denser portions

Compact servings that deliver full protein and micronutrient loads without the volume a GLP-1 user can no longer finish.

Fortified convenience

Shakes, bars, and ready meals engineered to hit protein and fiber targets in one small, planned bite rather than a full plate.

Reformulated staples, not new SKUs

The durable play is often adding protein and fiber to products people already buy — meeting the behavior where it is instead of asking shoppers to adopt a new ritual.

The shelf follows

Large single-serve formats built for a hungry shopper can go from “value” to “waste” overnight.

The barrier

The GLP-1 consumer isn't a monolith, reformulation takes time, and it's still unproven how durably medicated shoppers change what they buy — or whether they churn off the drugs.

A poll number

Adoption is a poll number, not a permanent behavior.

The durable bet

Protein density, functional fiber, and satiety are good product moves regardless of GLP-1 penetration.

Build for the behavior

Build reformulations that pay off even if adoption plateaus tomorrow.

Bet on the durable behavior — eating for density and satiety — not on a drug-class adoption curve you can't yet forecast.

Show your work

Every number on this page is arithmetic on the article's single sourced figure — no new claims. Heights are true to scale; the drawn width of the column is exaggerated once pens go sub-pixel, and the scene says so on screen.

US adults ≈ 262,000,000 (Census 2025)
12% currently taking a GLP-1 (KFF poll, Nov 2025) → 31,440,000 people
One single-dose weekly pen ≈ 15 cm long
31,440,000 × 0.15 m = 4,716 km stacked — 11.6× the ISS's ~400 km altitude
Laid down: 4,716 km vs LA–NY 3,944 km → +772 km past New York
31,440,000 ÷ 604,800 s ≈ 52 injections every second, around the clock

The altitude ladder — every rung is pens × 15 cm
Pens stacked	Height	Checkpoint
20	3.0 m	Basketball rim
620	93 m	Statue of Liberty
2,200	330 m	Eiffel Tower
5,520	828 m	Burj Khalifa
59,000	8.85 km	Everest
78,000	11.7 km	Airliner cruising altitude
667,000	100 km	Kármán line — edge of space
2,700,000	405 km	The ISS
31,440,000	4,716 km	12× higher than the ISS

The numerate honesty footnote

Self-report polls run hotter than the analyst counts: J.P. Morgan put roughly 10M Americans on a GLP-1 in 2025, against the ~31M this stack is built from. Even at that floor the line of pens runs about 1,500 km — New York past Atlanta. The stack visualizes the KFF poll faithfully — and says so.

What's exaggerated, exactly

Checkpoint heights are exact. The column's drawn width is not: a real 1.9 cm barrel is far under one pixel once the frame is 90 m tall, so above ~30 m the column is drawn at ~0.3–0.4% of the visible frame and its banding stands in for many pens rather than one each. The climb is framed in log scale — each checkpoint is roughly 10× the last.

Sources

KFF— ~1 in 8 US adults on a GLP-1 medication (poll, November 2025). The article's single hard number, and the only source Scenes 0–6 and 8–9 rely on.
Cornell / Numerator, Journal of Marketing Research, December 2025 — households with a GLP-1 user cut grocery spend 5.3% within six months (more than 8% among higher-income households); savory snacks about −10%. Published 18 December 2025; ~150,000-household Numerator panel. Used only for Scene 7's basket.
Nestlé — Vital Pursuit, announced May 2024 and on shelves nationwide by Q4, a 12-SKU launch lineup built for GLP-1 users (since extended). Shown in Scene 6 as a citation chip, not a brand replica.
Conagra — Healthy Choice “GLP-1 Friendly / On Track” badge program, January 2025, 26 products. Same treatment.
J.P. Morgan— an estimated ~10M Americans on a GLP-1 in 2025 (rising toward ~25M by 2030). An analyst headcount, not a claims-based prescription count. Used only in Scene 2's honesty footnote.
Landmark heights (basketball rim, Statue of Liberty, Eiffel Tower, Burj Khalifa, Everest, the Kármán line, the ISS) are public reference figures; the LA–NY great circle is 3,944 km.

Nine scenes, built in Blender and rendered live in WebGL. Clay set, baked ambient occlusion, no textures. Generic injector pen throughout — no brand trade dress. No body imagery: every human is an abstract massing. Scene 2's checkpoint heights are true to scale; the column's drawn width is not, and says so on screen.

Frequently asked questions

How are GLP-1 drugs affecting the food industry?: With roughly one in eight US adults now taking a GLP-1 medication (KFF poll, November 2025), demand is reshaping product design toward high protein, functional fiber, satiety, and muscle retention in nutrient-dense, compact formats. Because these drugs suppress appetite, users eat less, so every bite has to carry more nutrition — accelerating the food-as-medicine shift. There is no reliable market-size dollar figure for the category yet; the hard number is the KFF adoption stat.
What are GLP-1 friendly foods?: Foods designed for GLP-1 users prioritize nutrient density per bite over volume: high protein to preserve muscle during rapid weight loss, functional fiber for digestion and satiety, and micronutrient fortification to prevent shortfall on lower total intake. In practice that means high-protein shakes, bars, and ready meals, fortified staples, and smaller, denser portions rather than a distinct new food category.
Will the GLP-1 food trend last?: The durable part — reformulating toward protein, fiber, and satiety — is a sound product move regardless of how GLP-1 adoption evolves, because it serves the broader food-as-medicine and personalized-nutrition shift. The uncertain part is the drug-driven demand itself: a meaningful share of users churn off these medications, and it's unproven how durably medicated shoppers change what they buy. Build for the behavior, not the hype cycle.
How many people are on GLP-1 medications?: Roughly one in eight US adults now takes a GLP-1 medication, according to a KFF poll from November 2025. That is a national adoption figure, not a projection — and it's the single hard number underpinning the GLP-1 food trend, since no credible market-size dollar estimate for GLP-1-oriented foods exists yet.